Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CellCentric Ltd. and Takeda collaborate on epigenetics
January 2009
SHARING OPTIONS:

CAMBRIDGE, U.K.CellCentric, a biotechnology company specializing in epigenetic control mechanisms, recently signed an agreement with Takeda Pharmaeceuticals that covers further validation of an epigenetic target. Early evidence suggests that the protein plays an important role in cancer and inhibitors to the target could offer new ways to treat the disease. Takeda also has an option to licence the development program.

"It is clear that epigenetics is increasingly seen as a key area for target discovery and product development. We are delighted to build our relationship with Takeda, who are showing real commitment to the area," says Dr. Will West, chief executive of CellCentric. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.